<DOC>
	<DOCNO>NCT02013778</DOCNO>
	<brief_summary>Primary Phase I : To determine dose limit toxicity maximum tolerate dose ( MTD ) oral administration hydroxychloroquine ( HCQ ) conjunction transarterial chemoembolization ( TACE ) treat hepatocellular carcinoma ( HCC ) . A conventional 3+3 design utilized . Primary Phase II : To evaluate complete response rate cohort patient treat MTD , A Simon 's Optimal Two-stage design utilized .</brief_summary>
	<brief_title>Phase 1-2 Trial HCQ Plus TACE Unresectable HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patient capable give informed consent Patient diagnose hepatocellular carcinoma lob liver one follow method ( Pathologically confirm HCC biopsy HCC 2 cm classic radiographic finding arterial phase enhancement venous phase washout pseudocapsule formation contrast enhance MRI CT Lesion great 2 cm probable imaging feature HCC image finding cirrhosis and/or portal hypertension serum alphafetoprotein ( AFP ) great 200 mg/mL . Patient candidate orthotopic liver transplantation Hospital University Pennsylvania base review patient image history multidisciplinary Hepatic Tumor Conference Hospital University Pennsylvania . Age 18 year old Albumin 2.4 g/dL ; Total bilirubin 2 mg/dL ; INR 1.5 Creatinine 2.0 mg/dL , AST 121 IU/L ; ALT 189 IU/L ChildTurcottePugh Classification A B Eastern Clinical Oncology Group performance status 0 or1 . Prior TACE Active GI hemorrhage within 2 week study enrollment Ascites refractory medical therapy Contraindication receive HCQ TACE Unilobar HCC Contraindication contrast enhance MRI ( i.e . unable undergo followup image ) Women pregnant Participation another concurrent treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>outside transplant criterion</keyword>
</DOC>